Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997519 | 0.77 | HPGD (0.46) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL486988 | 0.75 | HPGD (0.47) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL15974565 | 0.73 | HPGD (0.50) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL31332733 | 0.72 | HPGD (0.45) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL20825485 | 0.72 | HPGD (0.45) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL2999547 | 0.70 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL24441184 | 0.69 | SLC6A3 (0.31) | ALDH1A1 | |
| SCHEMBL16369438 | 0.69 | TP53 (0.41) | — | |
| SCHEMBL2997520 | 0.68 | HPGD (0.44) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL6854602 | 0.67 | ATM (0.43) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | ALDH1A1 4279/4885HPGD 3877/4885LMNA 637/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | ALDH1A1 4279/4885HPGD 3877/4885LMNA 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.